Africa Malaria Treatment Market – Industry Trends and Forecast to 2031

Africa Malaria Treatment Market, By Agent (Plasmodium Falciparum, P.Vivax, P.Ovale, P.Malariae, P.Knowlelsi), Type (Medication, Vaccination, Others), Treatment Type (Suppressive Treatment, Radical Treatment), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) – Industry Trends and Forecast to 2031.

Africa Malaria Treatment Market Analysis and Size

Malaria is an infectious disease, which spreads through a bite of an infected female Anopheles mosquito, transferring parasites into the human body. Furthermore, these parasites lodge into liver cells, where they multiply and grow. The major factors that drive the Africa malaria treatment market are the increase in awareness initiatives by governments and the surge in research for new antimalarial drugs. However, lack of awareness about healthcare in developing countries is a major factor restraining market growth. An increase in the production, import, and export of hydroxychloroquine and chloroquine is expected to act as an opportunity for the market. Adverse effects and risks associated with anti-malaria drugs are expected to act as a challenge for the market.                                

Data Bridge Market Research analyzes that the Africa malaria treatment market, which was USD 51.35 million in 2023, is likely to reach USD 64.78 million by 2031 and is expected to undergo a CAGR of 6.4% during the forecast period. “Vaccination” dominates the type segment of the malaria treatment market due to the rising focus on vaccination programs and campaigns. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Malaria treatment involves a multi-pronged approach aimed at combating the parasitic infection caused by Plasmodium species transmitted through mosquito bites. The primary goal is to eliminate the parasites from the bloodstream and prevent complications. Typically, antimalarial medications are employed based on the species of the parasite and the severity of the infection. Artemisinin-based combination therapies (ACTs) are often the frontline drugs due to their efficacy in targeting the parasite's lifecycle. Other medications such as chloroquine, quinine, or atovaquone-proguanil might be used depending on drug resistance patterns.             

Africa Malaria Treatment Market Dynamics

Drivers

• Rising technological advancements

Advances in technology, such as improved diagnostic tools and innovative treatment approaches, drive progress in malaria treatment. Access to rapid diagnostic tests (RDTs), point-of-care devices, and mobile health solutions can revolutionize the diagnosis and management of malaria.

• Improved healthcare infrastructure

Strengthening healthcare infrastructure, especially in underserved rural areas, presents an opportunity to enhance access to quality healthcare services. Building clinics, training healthcare workers, and ensuring the availability of essential medical supplies can significantly impact malaria treatment outcomes.

Opportunities

• Innovation in drug development

There's an opportunity for pharmaceutical companies and researchers to develop new, more effective antimalarial drugs. Investing in research and development can lead to the discovery of novel compounds that combat drug-resistant strains and have fewer side effects, potentially revolutionizing malaria treatment.

• Increasing public private partnerships

Collaboration between governments, non-governmental organizations, philanthropic foundations, and private companies presents an opportunity to pool resources and expertise. Public-private partnerships can facilitate funding for research, infrastructure development, and the distribution of medications and mosquito control measures.

Restraints

• Regulatory approvals and compliance

Regulatory bodies in African countries are responsible for approving and registering medications, ensuring they meet safety and efficacy standards. However, varying regulatory frameworks across different countries can create hurdles for pharmaceutical companies aiming to introduce new drugs to multiple markets simultaneously. Delays in approvals impact the availability of potentially beneficial medications.

• Drug resistance

The emergence of drug-resistant strains of the malaria parasite has been a significant hurdle. Resistance to commonly used antimalarial drugs like chloroquine and sulfadoxine-pyrimethamine has complicated treatment and necessitated the adoption of more expensive and complex therapies.

Challenge

• Diagnostic limitations

Accurate and timely diagnosis of malaria is crucial for effective treatment. However, access to reliable diagnostic tools, particularly in remote areas, is a challenge. Rapid diagnostic tests (RDTs) are not always readily available or affordable, leading to misdiagnosis or delayed treatment.

This malaria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the malaria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2018, Cipla Ltd. received confirmation of approval from the World Health Organization (WHO) Prequalification Programme for their 100mg rectal artesunate suppositories (RAS). It is for the pre-referral management of severe malaria. It has enhanced the market growth of the company
• In July 2018, Lupin Pharmaceuticals, Inc. announced that its hydroxychloroquine sulfate tablets got approval from USFDA. The approval has accelerated the company's growth trajectory, particularly in the long term, which is anticipated to strengthen its position in the market

Africa Malaria Treatment Market Scope

The Africa malaria treatment market is segmented into seven notable segments based on agent, type, treatment, drug type, route of administration, end user and distribution channel.

Agent

• Plasmodium Falciparum
• P. Vivax
• P. Ovale
• P. Malariae
• P. Knowlelsi.

Type                                                                     

• Medication
• Vaccination
• Others

Treatment

• Suppressive treatment
• Radical treatment

Drug Type

• Branded
• Generics

Route of Administration

• Oral
• Parenteral

End User

• Hospitals
• Specialty clinics
• Home healthcare
• Others

Distribution Channel

• Direct tender
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Others

Malaria Treatment Market Country Analysis/Insights

The Africa malaria treatment market is segmented into seven notable segments based on agent, type, treatment, drug type, route of administration, end user and distribution channel.

The countries covered in the market report are Nigeria, Democratic Republic of Congo, Uganda, Coste D’ Ivoire, Niger, Kenya, Egypt, South Africa, and the rest of Africa.

Nigeria is expected to dominate and grow with the most promising growth due to the rapidly increasing patients and advancements in technology.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of African brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.   

Competitive Landscape and Africa Malaria Treatment Market Share Analysis

The Africa malaria treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Africa malaria treatment market.

Some of the major players operating in the Africa malaria treatment market are:

• Hikma Pharmaceuticals PLC (U.K.)
• Sun Pharmaceutical Industries Ltd. (India)
• Zydus Cadila (India)
• Cipla Inc. (India)
• GlaxoSmithKline plc. (U.K.)
• Bliss GVS Pharma Ltd. (India)
• MMV (Switzerland)
• Novartis AG (Awitzerland)
• Taj Pharmaceuticals Limited (India)
• Lupin Pharmaceuticals, Inc. (A Subsidiary of Lupin Limited) (India)
• AJANTA PHARMA (India)
• Strides Pharma Science Limited (India)
• sanofi-aventis U.S. LLC (A Subsidiary of Sanofi) (France)
• Viatris Inc. (U.S.)